title: Steroid sidestep: evading androgen ablation by abiraterone.
abstract: Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
authors.affiliation: Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. sharifn@ccf.org.
authors.forename: Nima
authors.initials: N
authors.lastname: Sharifi
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011374:Progesterone / Q000378:metabolism*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000235:genetics*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000736:Androstenes; D011944:Receptors, Androgen; D011374:Progesterone; D013254:Steroid 17-alpha-Hydroxylase